Program
urinastatin
Also written as “Ulinastatin” and “ulinastatin”.
Its studies are mostly in Respiratory Distress Syndrome · Pancreatitis · Heart Defects, Congenital, led by Shanghai Pharmaceuticals.
Furthest: phase 4, since May 26, 20104 company-led studies, 1 open or runningNext primary completion: Mar 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai Pharmaceuticals | 41 open or running | phase 4since May 26, 2010 | May 26, 2010 | Mar 2027phase 1 · NCT07923578 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 26, 2010First study: phase 4 study in PancreatitisFirst studyNCT01132521 · 252 enrolled · China
- Dec 18, 2014Phase 4 study in Heart Defects, CongenitalNCT02527811 · 450 enrolled · China
- Jul 21, 2016Phase 2 study in Respiratory Distress SyndromeNCT02895191 · 60 enrolled · China
- Oct 21, 2026Phase 1 study in Healthy ParticipantsNCT07923578 · 40 planned · China
Ahead
- Mar 2027Primary completion: phase 1 study in Healthy ParticipantsNCT07923578
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07923578Healthy Participants · China | 1 | Not yet recruiting | Mar 2027 | 40 |
| NCT02895191Respiratory Distress Syndrome · China | 2 | UNKNOWN | Sep 2019 | 60 |
| NCT02527811Heart Defects, Congenital · China | 4 | UNKNOWN | Jun 2018 | 450 |
| NCT01132521Pancreatitis · China | 4 | Suspended | Dec 2018 | 252 |
How it is read
Names in the registry
- “Ulinastatin”, 2 entries
- “ulinastatin”, 2 entries
Conditions, from the studies’ own filings
- Respiratory Distress Syndrome, 1 study
- Pancreatitis, 1 study
- Heart Defects, Congenital, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.